Volume 3.21 | Jun 8

Prostate Cell News 3.21 June 8, 2012
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter

Vav3-Rac1 Signaling Regulates Prostate Cancer Metastasis with Elevated Vav3 Expression Correlating with Prostate Cancer Progression and Posttreatment Recurrence
Scientists investigated the role of the guanine nucleotide exchange factor Vav3 in prostate cancer progression and metastasis and found that Vav3 expression correlated positively with prostate cancer cell migration and invasion. [Cancer Res] Abstract

Whitepaper: Automated Cell Isolation Enables More Relevant HIV Models

PUBLICATIONS (Ranked by impact factor of the journal)


SPRY2 Loss Enhances ErbB Trafficking and PI3K/AKT Signalling to Drive Human and Mouse Prostate Carcinogenesis

Investigators report evidence for a positive feedback regulation of the ErbB-PI3K/AKT cascade by Sprouty 2 (SPRY2) loss in in vitro as well as pre-clinical in vivo models and clinical prostate cancer. [Embo Mol Med] Abstract

The Stress Response Mediator ATF3 Represses Androgen Signaling by Binding the Androgen Receptor
Investigators report that activating transcription factor 3 (ATF3) can directly bind the androgen receptor (AR) and consequently repress AR-mediated gene expression. [Mol Cell Biol] Abstract

A Regulatory Feedback Loop between Ca2+/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) and the Androgen Receptor in Prostate Cancer Progression

Researchers suggest that in prostate cancer progression, CaMKK2 and the androgen receptor (AR) are in a feedback loop in which CaMKK2 is induced by the AR to maintain AR activity, AR dependent cell cycle control and continued cell proliferation. [J Biol ChemAbstract | Full Article

Retigeric Acid B Exhibits Antitumor Activity through Suppression of Nuclear Factor-KB Signaling in Prostate Cancer Cells In Vitro and In Vivo
Researchers found that using PC3 and DU145 cells as models, retigeric acid B inhibited phosphorylation levels of IκBa and p65 subunit of nuclear factor-κB in a time- and dosage-dependent manner. [PLoS One] Full Article

Triptolide Inhibits the Proliferation of Prostate Cancer Cells and Down-Regulates SUMO-Specific Protease 1 Expression
Investigators demonstrated that triptolide inhibited cell growth and induced cell death in LNCaP and PC-3 cell lines. [PLoS One] Full Article

Role of Glyoxalase I in the Proliferation and Apoptosis Control of Human LNCaP and PC3 Prostate Cancer Cells
Scientists aimed to clarify whether glyoxalase I was involved in the proliferation control of LNCaP and PC3 human prostate cancer cells or if it played a different role in the growth regulation of these cells. [Prostate] Abstract

Bradykinin Enhances Cell Migration in Human Prostate Cancer Cells through B2 Receptor/PKCd/C-Src Dependent Signaling Pathway
Researchers investigated whether bradykinin is associated with migration of prostate cancer cells. [Prostate] Abstract

Ardisianone, a Natural Benzoquinone, Efficiently Induces Apoptosis in Human Hormone-Refractory Prostate Cancers through Mitochondrial Damage Stress and Survivin Downregulation

Ardisianone displayed anti-proliferative and apoptotic activities against human hormone-refractory prostate cancer cells, PC-3, and DU-145. [Prostate] Abstract


An Immunohistochemical Signature Comprising PTEN, MYC, and Ki67 Predicts Progression in Prostate Cancer Patients Receiving Adjuvant Docetaxel after Prostatectomy
Researchers examined PTEN and additional protein markers in primary tumors from patients with high-risk, localized prostate cancer who received adjuvant docetaxel in a prospective multicenter trial. [Cancer] Abstract

Paclitaxel in Combination with Carboplatin as Salvage Treatment in Patients with Castration Resistant Prostate Cancer: A Hellenic Oncology Research Group Multicenter Phase II Study

Scientists evaluated the efficacy and tolerance of biweekly paclitaxel and carboplatin combination in patients with castration-resistant prostate cancer. [Cancer Chemother Pharmacol] Abstract

Ready Sep Go: Request a Free Cell Isolation Wallchart


Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue in Advanced Prostate Cancer
Exelixis, Inc. reported positive updated interim data from an ongoing phase II trial of cabozantinib in men with metastatic castration-resistant prostate cancer and bone metastases. [Press release from Exelixis, Inc. discussing research presented at the American Society of Clinical Oncology (ASCO) 2012, Chicago] Press Release

ZYTIGA® Plus Prednisone Show Improvements in Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer
Results observed from pre-specified interim analyses of a randomized, placebo-controlled phase III study demonstrated that patients with metastatic castration-resistant prostate cancer treated with ZYTIGA® plus prednisone showed a statistically significant improvement in radiographic progression-free survival and all secondary endpoints compared to patients treated with placebo plus prednisone. [Press release from Janssen Biotech, Inc. discussing research presented at the American Society of Clinical Oncology (ASCO) 2012, Chicago] Press Release


Medivation and Astellas Provide Update on PREVAIL Enrollment
Medivation, Inc.and Astellas Pharma Inc. announced the completion of targeted enrollment of 1,680 patients in the PREVAIL study, a global phase III clinical trial evaluating enzalutamide in men with advanced prostate cancer who have not yet received chemotherapy. [Medivation, Inc.] Press Release

Bristol-Myers Squibb Announces Global Collaboration with Leading Academic Institutions to Advance Science of Immuno-Oncology

Bristol-Myers Squibb Company announced the formation of the International Immuno-Oncology Network, a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology. [Business Wire] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Stem Cell Society Singapore Symposium 2012
September 6-7 2012
Singapore, Singapore

Visit our events page to see a complete list of events in the prostate cell community.


Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

Associate Research Scientist (Columbia University Medical Center)

Clinical Research Associate (Jennerex Biotherapeutics, Inc.)

Postdoctoral Position – Cancer Genomics (University of California)

Research Associate – Development (Precision Therapeutics, Inc.)

Recruit Top Talent:
Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us